{"id":27595,"date":"2014-12-01T08:08:01","date_gmt":"2014-12-01T08:08:01","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=27595"},"modified":"2014-12-01T10:08:49","modified_gmt":"2014-12-01T10:08:49","slug":"us-activists-called-on-gilead-to-set-a-per-treatment-price-for-sofosbuvirledipasvir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/27595","title":{"rendered":"US activists called on Gilead to set a per-treatment price for sofosbuvir\/ledipasvir"},"content":{"rendered":"<p><strong>In a press release on 13th October 2014, the Fair Pricing Coalition, a US treatment activist organisation, called for Gilead to set a single uniform per-cure price for the coformulation of sofosbuvir and ledipasvir (brand name Harvoni) irrespective or whether 8, 12, or 24 weeks of treatment is required.<\/strong><\/p>\n<p>&#8220;The FPC, a coalition of HIV and viral hepatitis treatment activists, recognises the significant advance in treatment success and convenience of Harvoni, but is disappointed at the Wholesale Acquisition Cost (WAC) of $1,125 per once-daily tablet, or $63,000, $94,500, and $189,000 for an 8-, 12-, and 24-week course of treatment, respectively.&#8221;<\/p>\n<p>&#8220;The FPC maintains that these costs, particularly for the 12- and 24- week courses of treatment, are exorbitant. Since they are now published, however, FPC concludes that the WAC of $63,000 for eight weeks of Harvoni, which is projected to be the most common duration of treatment as more people living with genotype 1 hepatitis C learn of their infection and seek care, should be made the uniform cost per cure, regardless of the length of therapy.&#8221;<\/p>\n<p>Reference:<\/p>\n<p>Fair Pricing Coalition. Fair Pricing Coalition welcomes approval of Gilead Sciences&#8217; combination tablet for hepatitis C, urges a uniform price for curative treatment. (13 October 2014).<br \/>\n<a href=\"http:\/\/fairpricingcoalition.org\">http:\/\/fairpricingcoalition.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a press release on 13th October 2014, the Fair Pricing Coalition, a US treatment activist organisation, called for Gilead to set a single uniform per-cure price for the coformulation of sofosbuvir and ledipasvir (brand name Harvoni) irrespective or whether &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-27595","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/27595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=27595"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/27595\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=27595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=27595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=27595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}